Related Experiment Video
Updated: Jan 21, 2026

Clarifying and Imaging Candida albicans Biofilms
Published on: March 6, 2020
Release of different amphotericin B formulations from PMMA bone cements and their activity against Candida biofilm
Magdalena Czuban1, Dag Wulsten2, Lei Wang3
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Center for Musculoskeletal Surgery (CMSC), Germany; Freie Universität, Institute of Chemistry and Biochemistry, Berlin, Germany; Berlin-Brandenburg School for Regenerative Therapies (BSRT), Germany.
Abstract:
Amphotericin B is used for local delivery from polymethylmethacrylate to treat fungal prosthetic joint infections. The optimal amphotericin B formulation and the influence of different poragens in the bone cements are unknown. To investigate the necessary amount of amphotericin B in the bone cement to prevent Candida biofilm several amphotericin B formulations were studied: non-liposomal and liposomal with or without poragen gentamicin. For the non-liposomal formulation, standard bile salt, the sodium deoxycholate, was used and additionally N-methyl-D-glucamine/palmitate was applied. The activity of the released amphotericin B was tested against C. albicans, C. glabrata, C. parapsilosis and C. krusei biofilms with application of the isothermal calorimeter and standard microbiological methods. Compressive strength was measured before and after antifungal elution from the cements. There is less aggregated N-methyl-D-glucamine/palmitate amphotericin B released but its antifungal activity is equivalent with the deoxycholate amphotericin B. The minimum quantity of antifungal preventing the Candida biofilm formation is 12.5 mg in gram of polymer powder for both non-liposomal formulations. The addition of gentamicin reduced the release of sodium deoxycholate amphotericin B. Gentamicin can be added to N-methyl-D-glucamine/palmitate amphotericin B in order to boost the antifungal release. When using liposomal amphotericin B more drug is released. All amphotericin B formulations were active against Candida biofilms. Although compressive strength slightly decreased, the obtained values were above the level of strength recommended for the implant fixation. The finding of this work might be beneficial for the treatment of the prosthetic joint infections caused by Candida spp.
Insights
This study determined the optimal amphotericin B formulation for preventing fungal prosthetic joint infections. A minimum of 12.5 mg/g of non-liposomal amphotericin B is effective against Candida biofilms.
Area of Science:
- Biomaterials Science
- Mycology
- Infectious Diseases
Background:
- Polymethylmethacrylate (PMMA) bone cements are used for local delivery of amphotericin B to treat fungal prosthetic joint infections.
- Optimal amphotericin B formulations and the impact of poragens in bone cements remain unclear.
- Understanding these factors is crucial for effective treatment of Candida spp. infections.
Purpose of the Study:
- To investigate the optimal amphotericin B formulation for preventing Candida biofilm formation in PMMA bone cements.
- To evaluate the influence of different poragens, including gentamicin, on amphotericin B release and antifungal activity.
- To determine the minimum effective concentration of amphotericin B in bone cement against various Candida species.
Main Methods:
- Preparation and testing of various amphotericin B formulations (non-liposomal, liposomal, with/without gentamicin) incorporated into PMMA bone cement.
- Assessment of antifungal activity against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei biofilms using isothermal calorimetry and standard microbiological methods.
- Measurement of cement compressive strength before and after antifungal elution.
Main Results:
- Both sodium deoxycholate and N-methyl-D-glucamine/palmitate non-liposomal amphotericin B formulations demonstrated equivalent antifungal activity, with a minimum effective concentration of 12.5 mg/g against Candida biofilms.
- Liposomal amphotericin B formulations showed increased drug release.
- The addition of gentamicin reduced the release of sodium deoxycholate amphotericin B but could enhance release when combined with N-methyl-D-glucamine/palmitate amphotericin B.
Conclusions:
- All tested amphotericin B formulations were effective against Candida biofilms, with 12.5 mg/g of non-liposomal drug being sufficient.
- While compressive strength slightly decreased, it remained above recommended levels for implant fixation.
- These findings offer valuable insights for optimizing the treatment of prosthetic joint infections caused by Candida species.
Related Concept Videos
Hydration of Cement
Soundness of Cement
Portland Cement
Fineness of Cement
Direct...
Strength of Cement
For compressive strength tests, ASTM C 109-05 standards prescribe a cement-sand mix ratio of 1:2.75 and a water/cement ratio of 0.485 for making 2-inch cubes. These cubes are mixed, cast, and cured in saturated lime water at 23°C until testing. Flexural strength testing, outlined in...
Types of Cement I
Type I (Ordinary Portland Cement) is widely used for general construction where special properties are not required. It has moderate sulfate resistance and heat of hydration.
Type II (Modified Cement) offers moderate resistance to sulfate attack and a lower rate of heat development compared to Type I. It is suitable for structures in...

